{
    "organizations": [],
    "uuid": "19e6c11578ac3c5725736ac88225e79a5f5af7a3",
    "author": "",
    "url": "https://www.reuters.com/article/brief-puma-biotechnology-says-emas-chmp/brief-puma-biotechnology-says-emas-chmp-has-communicated-a-negative-trend-vote-for-its-breast-cancer-treatment-neratinib-idUSFWN1PI18F",
    "ord_in_thread": 0,
    "title": "BRIEF-Puma Biotechnology Says EMA's CHMP Has Communicated A Negative Trend Vote For Its Breast Cancer Treatment, Neratinib",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 23, 2018 / 9:33 PM / Updated 8 minutes ago BRIEF-Puma Biotechnology Says EMA's CHMP Has Communicated A Negative Trend Vote For Its Breast Cancer Treatment, Neratinib Reuters Staff 1 Min Read \nJan 23 (Reuters) - Puma Biotechnology Inc: \n* PUMA BIOTECHNOLOGY ANNOUNCES RESULTS OF CHMP ORAL EXPLANATION FOR NERATINIB FOR EXTENDED ADJUVANT TREATMENT OF HER2-POSITIVE EARLY STAGE BREAST CANCER \n* PUMA BIOTECHNOLOGY - CHMP USE OF EMA COMMUNICATED NEGATIVE TREND VOTE AFTER MEETING WITH CO TO DISCUSS MAA FOR NERATINIBâ€‹ \n* PUMA BIOTECHNOLOGY - NEGATIVE TREND VOTE MEANS IT IS UNLIKELY CHMP WILL PROVIDE POSITIVE OPINION RELATED TO MAA AT FORMAL DECISION VOTE IN FEB. 2018 \n* PUMA BIOTECHNOLOGY - NEGATIVE TREND VOTE ALSO MEANS ADDITIONAL STEPS WOULD NEED TO BE TAKEN TO GAIN MARKETING APPROVAL IN EUROPE \n* PUMA BIOTECHNOLOGY - CHMP INDICATED BENEFIT RISK ASSESSMENT NEGATIVE AS STUDY RESULTS BASED ON EVIDENCE FROM SINGLE PIVOTAL TRIAL, AMONG OTHER THINGS \n* PUMA BIOTECH -CHMP INDICATED BENEFIT RISK ASSESSMENT ALSO NEGATIVE AS 2- & 5-YEAR IDFS BENEFITS OBSERVED TO-DATE MAY LACK SUFFICIENT CLINICAL RELEVANCE Source text for Eikon: Further company coverage:",
    "published": "2018-01-23T23:33:00.000+02:00",
    "crawled": "2018-01-23T23:47:35.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "biotechnology",
        "say",
        "ema",
        "chmp",
        "communicated",
        "negative",
        "trend",
        "vote",
        "breast",
        "cancer",
        "treatment",
        "neratinib",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "puma",
        "biotechnology",
        "inc",
        "puma",
        "biotechnology",
        "announces",
        "result",
        "chmp",
        "oral",
        "explanation",
        "neratinib",
        "extended",
        "adjuvant",
        "treatment",
        "early",
        "stage",
        "breast",
        "cancer",
        "puma",
        "biotechnology",
        "chmp",
        "use",
        "ema",
        "communicated",
        "negative",
        "trend",
        "vote",
        "meeting",
        "co",
        "discus",
        "maa",
        "puma",
        "biotechnology",
        "negative",
        "trend",
        "vote",
        "mean",
        "unlikely",
        "chmp",
        "provide",
        "positive",
        "opinion",
        "related",
        "maa",
        "formal",
        "decision",
        "vote",
        "puma",
        "biotechnology",
        "negative",
        "trend",
        "vote",
        "also",
        "mean",
        "additional",
        "step",
        "would",
        "need",
        "taken",
        "gain",
        "marketing",
        "approval",
        "europe",
        "puma",
        "biotechnology",
        "chmp",
        "indicated",
        "benefit",
        "risk",
        "assessment",
        "negative",
        "study",
        "result",
        "based",
        "evidence",
        "single",
        "pivotal",
        "trial",
        "among",
        "thing",
        "puma",
        "biotech",
        "indicated",
        "benefit",
        "risk",
        "assessment",
        "also",
        "negative",
        "idf",
        "benefit",
        "observed",
        "may",
        "lack",
        "sufficient",
        "clinical",
        "relevance",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}